Journal Article

Hospital Outbreak of Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Producing VIM-1, a Novel Transferable Metallo-β-Lactamase

Giuseppe Cornaglia, Annarita Mazzariol, Laura Lauretti, Gian Maria Rossolini and Roberta Fontana

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 31, issue 5, pages 1119-1125
Published in print November 2000 | ISSN: 1058-4838
Published online November 2000 | e-ISSN: 1537-6591 | DOI:
Hospital Outbreak of Carbapenem-Resistant Pseudomonas aeruginosa Producing VIM-1, a Novel Transferable Metallo-β-Lactamase

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


A total of 8 Pseudomonas aeruginosa isolates was collected from 7 different patients in different wards of the University Hospital of Verona, Italy, from February 1997 to February 1998. The high level of resistance to carbapenems (imipenem minimum inhibitory concentration was always >128 µg/mL) and other broad-spectrum β-lactams and the rate of imipenem hydrolysis and its inhibition by ethylenediamine-tetra-acetic acid were all suggestive of production of a carbapenem-hydrolyzing metallo-β-lactamase. A specific DNA probe derived from the recently cloned blaVIM-1 gene hybridized to all the isolates. A genomic DNA fingerprinting profile revealed clonal relatedness for 7 of 8 isolates. A description of this hospital outbreak is reported, the occurrence of which confirms that proliferation of metallo-β-lactamase-producing strains multiply resistant to β-lactams is already a reality outside Japan. These findings emphasize the need for early recognition of similar isolates.

Journal Article.  4783 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.